HEERLEN, the Netherlands, September 19, 2016
HEERLEN, the Netherlands, September 19, 2016 /PRNewswire/ --
Royal DSM, a global science-based company active in health, nutrition and materials, announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75 % .
The new bond issue takes advantage of favorable market conditions and allows the company to lock in low interest rates taking into account the maturing of a €750 million bond in 2017.
The terms are laid down in the €4 billion Debt Issuance Program of Royal DSM, the final terms and the supplements thereto being available on the company's website.
The re-offer price was 99.799%. Based on this price the yield is 0.771%. The bond will be listed on Euronext Amsterdam shortly.
This release does not constitute an offer or an invitation to subscribe for or purchase any securities. The notes are being offered only by means of a prospectus.
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
For more information:
PRN NLDPR Newswire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.